Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

RON (recepteur d'origine nantais) and MET (hepatocyte growth factor receptor) are tyrosine kinase receptors. Various cancers have aberrant RON and MET expression and activation, which contribute to cancer cell proliferation, invasiveness, and metastasis. Here, we explored RON and MET expression in p...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chen-Yu Hu, Xiang-Ming Xu, Bo Hong, Zhi-Gang Wu, Yun Qian, Tian-Hao Weng, Yi-Zhi Liu, Tao-Ming Tang, Ming-Hai Wang, Hang-Ping Yao
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2019-12-01
Edice:	Frontiers in Oncology
Témata:	pancreatic cancer tyrosine kinase inhibitors RON receptor tyrosine kinase MET receptor tyrosine kinase prognosis biomarker therapeutic target
On-line přístup:	https://www.frontiersin.org/article/10.3389/fonc.2019.01377/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!